• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilars Articles for the Year 2019


The Center for Biosimilars® recaps the top stories for the year 2019.


Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the year 2019.

Number 5: In January, Pfizer confirmed that it made the decision to terminate 5 preclinical biosimilar programs after the results of the company’s annual investment review.

Number 4: Also in January, the FDA approved Samsung Bioepis’ Ontruzant, a biosimilar trastuzumab referencing Herceptin.

Number 3: In August, UnitedHealthcare indicated that it would prefer 2 oncology biosimilars in its commercial and community plans.

Number 2: In May, the FDA released its long-awaited final guidance on demonstrating interchangeability of a biosimilar with its reference.

Number 1: Finally, the US market got its first anticancer biosimilars in July when Amgen and Allergan launched biosimilar bevacizumab and trastuzumab.

To read all of these articles and more, visit centerforbiosimilars.com.

Recent Videos
Prerakkumar Parikh, PharmD
Cencora's Corey Ford
Brian Biehn
GBW 2023 webinar
Fran Gregory, PharmD, MBA
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Here are the top 5 biosimilar articles for the week of May 1, 2023.
Christine Baeder
Here are the top 5 biosimilar articles for the week of February 13th, 2023.
Michael Kleinrock
Related Content
© 2024 MJH Life Sciences

All rights reserved.